CREXONT Drug Patent Profile
✉ Email this page to a colleague
When do Crexont patents expire, and when can generic versions of Crexont launch?
Crexont is a drug marketed by Impax and is included in one NDA. There are ten patents protecting this drug.
This drug has thirty-two patent family members in thirteen countries.
The generic ingredient in CREXONT is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Crexont
A generic version of CREXONT was approved as carbidopa; levodopa by DR REDDYS LABS SA on August 28th, 1992.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CREXONT?
- What are the global sales for CREXONT?
- What is Average Wholesale Price for CREXONT?
Summary for CREXONT
International Patents: | 32 |
US Patents: | 10 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
What excipients (inactive ingredients) are in CREXONT? | CREXONT excipients list |
DailyMed Link: | CREXONT at DailyMed |
Pharmacology for CREXONT
Drug Class | Aromatic Amino Acid |
US Patents and Regulatory Information for CREXONT
CREXONT is protected by ten US patents and one FDA Regulatory Exclusivity.
Patents protecting CREXONT
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARKINSON'S DISEASE
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARKINSON'S DISEASE
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARKINSON'S DISEASE
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARKINSON'S DISEASE
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARKINSON'S DISEASE
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARKINSON'S DISEASE
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARKINSON'S DISEASE
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting CREXONT
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Impax | CREXONT | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 217186-004 | Aug 7, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Impax | CREXONT | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 217186-003 | Aug 7, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Impax | CREXONT | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 217186-003 | Aug 7, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Impax | CREXONT | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 217186-003 | Aug 7, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Impax | CREXONT | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 217186-003 | Aug 7, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Impax | CREXONT | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 217186-001 | Aug 7, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for CREXONT
See the table below for patents covering CREXONT around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 116801869 | 左旋多巴给药方案 (Levodopa dosing regimen) | ⤷ Sign Up |
Japan | 2019094353 | レボドパ及び/又はレボドパのエステルの粘膜付着性制御放出配合物、並びにその使用 (MUCOADHESIVE CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA, AND USES THEREOF) | ⤷ Sign Up |
Japan | 2024501235 | レボドパ投薬レジメン | ⤷ Sign Up |
European Patent Office | 3782614 | FORMULATIONS MUCOADHÉSIVES À LIBÉRATION CONTRÔLÉE DE LÉVODOPA ET/OU D'ESTERS DE LÉVODOPA ET LEURS UTILISATIONS (MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF) | ⤷ Sign Up |
Poland | 3054929 | ⤷ Sign Up | |
Canada | 3196650 | SCHEMA POSOLOGIQUE DE LEVODOPA (LEVODOPA DOSING REGIMEN) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |